November 2018

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) is having an incredibly strong start to the trading session in the pre-market hours this morning after announcing positive clinical results. The results come from the company’s Phase 3 clinical trial of EPIDIOLEX, a treatment that is derived from cannabis and is being assessed as an option for epilepsy. […]

by

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) is having an incredibly strong start to the trading session in the pre-market hours this morning after announcing positive clinical results. The results come from the company’s Phase 3 clinical trial of EPIDIOLEX, a treatment that is derived from cannabis and is being assessed as an option for epilepsy. […]

by

TORONTO, Nov. 28, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE:31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced its results for the three months ended September 30, 2018. The unaudited condensed interim consolidated financial statements and […]

by

TORONTO, Nov. 28, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE:31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced its results for the three months ended September 30, 2018. The unaudited condensed interim consolidated financial statements and […]

by

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome – Primary endpoint achieved with both EPIDIOLEX doses compared to placebo –  – Today’s data represents the fourth positive Phase 3 pivotal trial for EPIDIOLEX in Dravet syndrome and Lennox-Gastaut Syndrome – – EPIDIOLEX recently […]

by

PALM BEACH, Florida, November 27, 2018 /PRNewswire/ — Financialnewsmedia.com News Commentary  While there may have been a recent pull back on Cannabis stocks, one thing that remains strong is the grow operations show no signs of slowing and instead continue to expand. The cannabis industry’s growth is forcing industry cannabis focused companies to evaluate the […]

by

– Epidiolex® (cannabidiol) oral solution (CV), first FDA-approved plant-derived cannabinoid medicine launched in the U.S. – – Conference call today at 4:30 p.m. EST – LONDON and CARLSBAD, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of […]

by

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) just announced positive top-line results on Monday morning for the company’s cannabinoid-based childhood-onset epilepsy treatment EPIDIOLEX. The stock ramped higher by as much as nearly 6% in response and closed up nearly 3%. The data pertained to the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX (cannabidiol or […]

by

– Primary endpoint achieved with both EPIDIOLEX doses compared to placebo –  – Today’s data represents the fourth positive Phase 3 pivotal trial for EPIDIOLEX in Dravet syndrome and Lennox-Gastaut Syndrome – – EPIDIOLEX recently launched in the US and is now available by prescription –   LONDON, Nov. 26, 2018 (GLOBE NEWSWIRE) — GW […]

by

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome – Primary endpoint achieved with both EPIDIOLEX doses compared to placebo –  – Today’s data represents the fourth positive Phase 3 pivotal trial for EPIDIOLEX in Dravet syndrome and Lennox-Gastaut Syndrome – – EPIDIOLEX recently […]

by

– Primary endpoint achieved with both EPIDIOLEX doses compared to placebo –  – Today’s data represents the fourth positive Phase 3 pivotal trial for EPIDIOLEX in Dravet syndrome and Lennox-Gastaut Syndrome – – EPIDIOLEX recently launched in the US and is now available by prescription –   LONDON, Nov. 26, 2018 (GLOBE NEWSWIRE) — GW […]

by

India’s new-found love for ayurveda, its ancient medicine system, may help mainstream marijuana in the country. On Nov. 25, the Central Council For Research in Ayurvedic Sciences, a research body under India’s AYUSH ministry of traditional medicine, announced positive results from the first clinical study in India on the use of cannabis as a restorative drug […]

by

The Food and Drug Administration (FDA) has granted Orphan Drug designation for cannabidiol (CBD) to prevent ischemia and reperfusion injury resulting from solid organ transplantation.  The designation was granted to Revive Therapeutics, a company that specializes in cannabis-based pharmaceuticals. Previously, the Company was granted Orphan Drug status for cannabidiol in the treatment of autoimmune hepatitis.  […]

by

Researchers at the Indian Institute of Integrative Medicine (IIIM) are working with two compounds derived from cannabis to create potential drugs for treating epilepsy and extreme pain in cancer patients. The drug will contain tetrahydrocannabinol (THC) and cannabidiol (CBD), two of the nearly 120 components of cannabis. “There is a lot of misconception about cannabis […]

by